Novartis India Reports Q2: Revenue Up by 10.59% Year-on-Year

The comprehensive analytics outlining the performance and outlook of Novartis India Limited.‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Novartis India Limited.’s financial performance for the Q2(Sep 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 10.59 %. However, it did see a marginal slip of -5.62 % from the previous quarter. Expenses ticked up slightly by 1.19 % quarter-on-quarter, aligning with the annual rise of 11.79 %. Operating profit, while up 6.21 % compared to last year, faced a quarter-on-quarter dip of -25.04 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -0.85 %, but a shrinkage of -5.34 % sequentially. Other income fell by -0.86 % compared to the last quarter, despite an annual decline of -38.86 %. Interest expenses dropped significantly by -6.67 % from the previous quarter, yet the year-over-year decrease remains at a moderate -80.28 %. Depreciation costs climbed by 5.45 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -10.77 %. Profit before tax declined annually by -15.02 % but saw a reduction from the preceding quarter by -18.15 %.
Tax expenses as a percentage of profits decreased slightly by -1.04 % compared to last year, with a more notable quarter-on-quarter increase of 2.36 %. Net profit fell by -13.81 % year-on-year but witnessed a -20.68 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -13.76 % but a quarterly fall of -20.63 %. In summary, Novartis India Limited.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Novartis India Limited.’s 2024-25(Q2) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 10.59 % year-on-year growth, although there was a slight dip of -5.62 % from the previous quarter. Expenses rose by 11.79 % compared to the previous year, with a 1.19 % increase quarter-on-quarter. Operating Profit surged by 6.21 % annually, and saw a -25.04 % decrease from the last quarter.
Net Profit showed yearly decrease of -13.81 %, and experienced a -20.68 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -13.76 % annually, however dipped by -20.63 % compared to the last quarter. In essence, while Novartis India Limited. exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.